Literature DB >> 16813874

Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era.

Richard E Hautmann1, Jürgen E Gschwend, Robert C de Petriconi, Martina Kron, Bjoern G Volkmer.   

Abstract

PURPOSE: We studied the effect of radical cystectomy for transitional cell carcinoma of the bladder on survival and failure patterns when the 2 surgical standards cystectomy and neobladder were combined, when possible.
MATERIALS AND METHODS: A consecutive series of patients undergoing radical cystectomy with pelvic lymph node dissection for transitional cell carcinoma of the bladder with curative intent was analyzed. Patients with neoadjuvant radiotherapy/chemotherapy were excluded. Pathological characteristics based on the 2002 TNM system, recurrence-free/overall survival and metastatic patterns were determined.
RESULTS: A total of 788 patients with a mean age +/- SD of 65 +/- 10 years and a mean followup of 53.5 months who underwent surgery between 1986 and 2003 were analyzed. A neobladder was constructed in 75.4% of patients. Ten-year recurrence-free and overall survival rates were 59.1% and 44.9%, respectively. Positive lymph nodes were present in 143 patients (18%). The rate of recurrence-free survival at 5 years was 82.5% for pT2a pN0, 61.9% for pT2b and pT3a pN0, and 53.1% for pT3b pN0 disease. Local and distant failure rates were 4% and 9.5% for organ confined tumors, 15.9% and 19.2% for nonorgan confined tumors, and 20.4% and 45.1% in patients with positive lymph nodes, respectively.
CONCLUSIONS: In patients with organ confined, lymph node negative transitional cell carcinoma excellent survival data can be achieved as long as the tumor is limited to the inner half of the detrusor. These data on a large group of patients support early aggressive surgical management for invasive bladder cancer. The results of this surgery only series may serve as a reference for other treatment modalities for bladder cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16813874     DOI: 10.1016/j.juro.2006.03.038

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  97 in total

1.  Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

Authors:  Raymond H Mak; Daniel Hunt; William U Shipley; Jason A Efstathiou; William J Tester; Michael P Hagan; Donald S Kaufman; Niall M Heney; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

2.  Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy.

Authors:  Kevin R Kozak; Maryam Hamidi; Matthew Manning; John S Moody
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-06       Impact factor: 7.038

Review 3.  Current management of muscle-invasive bladder cancer.

Authors:  G Sancho; P Maroto; J Palou
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

4.  [Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")].

Authors:  M M Heck; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

5.  [Radical cystectomy - pro laparoscopic].

Authors:  J Rassweiler; K Godin; A S Goezen; D Kusche; P Chlosta; F Gaboardi; C C Abbou; R van Velthoven
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

Review 6.  [Update on chemotherapy for bladder cancer. Update 2010].

Authors:  M M Heck; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 7.  [Robot-assisted radical cystectomy: do we actually need a robot?].

Authors:  G Niegisch; P Albers; R Rabenalt
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

Review 8.  Delay of cystectomy: for whom does it really matter?

Authors:  Richard E Hautmann
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

Review 9.  [Systemic chemotherapy for bladder cancer: news in 2009].

Authors:  M Retz; J E Gschwend; J Lehmann
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

Review 10.  [Systemic treatment of bladder cancer].

Authors:  M Haas; M Burger; M J Schnabel
Journal:  Urologe A       Date:  2021-05-27       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.